<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05045716</url>
  </required_header>
  <id_info>
    <org_study_id>BAN2401-A001-004</org_study_id>
    <nct_id>NCT05045716</nct_id>
  </id_info>
  <brief_title>A Study of Subcutaneous Lecanemab in Healthy Participants</brief_title>
  <official_title>An Open-label, Parallel-group, Randomized Study to Evaluate the Absolute Bioavailability of Single Dose Subcutaneous Administration of Lecanemab in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eisai Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eisai Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to determine the absolute bioavailability and&#xD;
      pharmacokinetic (PK) profile of a single dose of lecanemab when administered subcutaneously&#xD;
      (SC) in healthy participants.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 7, 2021</start_date>
  <completion_date type="Anticipated">December 7, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 7, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC(0-t): Area Under the Serum Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration for Lecanemab</measure>
    <time_frame>Days 0-50</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-72h): Area Under the Serum Concentration-time Curve From Time Zero to 72 Hours Post End of Intravenous (IV) Infusion or SC Administration for Lecanemab</measure>
    <time_frame>0-72 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-inf): Area Under the Serum Concentration-time Curve From Time Zero to Time Extrapolated to Infinity for Lecanemab</measure>
    <time_frame>Days 0-50</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>F: Absolute Bioavailability of SC Formulation for Lecanemab</measure>
    <time_frame>Days 0-50</time_frame>
    <description>Absolute bioavailability (F) = [AUC(0-inf) SC*Dose (IV)]/[AUC(0-inf) IV*Dose (SC)]. IV dose will be based on total dose (mg) infused.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax: Maximum Observed Serum Concentration for Lecanemab</measure>
    <time_frame>Days 0-50</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax: Time to Reach Maximum Serum Concentration for Lecanemab</measure>
    <time_frame>Days 0-50</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>T1/2: Terminal Elimination Half-life for Lecanemab</measure>
    <time_frame>Days 0-50</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Reporting one or More Treatment-emergent Adverse Events (TEAEs)</measure>
    <time_frame>Baseline up to Day 50</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically Significant Change From Baseline in Laboratory Parameters</measure>
    <time_frame>Baseline up to Day 22</time_frame>
    <description>Clinical laboratory parameters will include hematology, blood chemistry, and urinalysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically Significant Change From Baseline in Vital Signs Values</measure>
    <time_frame>Baseline up to Day 50</time_frame>
    <description>Vital signs parameters will include diastolic and systolic blood pressure (BP), pulse, respiratory rate, body temperature and body weight.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically Significant Change From Baseline in 12-lead Electrocardiogram (ECG) Findings</measure>
    <time_frame>Baseline up to Day 50</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Positive and Negative Anti-drug Antibody (ADA) for Lecanemab</measure>
    <time_frame>Baseline Up to Day 50</time_frame>
    <description>ADA will be measured using validated electrochemiluminescent immunoassay (ECL) methods.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Neutralizing Antibodies (NAb) for Lecanemab</measure>
    <time_frame>Baseline up to Day 50</time_frame>
    <description>NAb will be measured using validated ECL methods.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Lecanemab 10 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive lecanemab 10 milligram per kilogram (mg/kg), as single dose IV infusion over approximately 1 hour on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lecanemab 700 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive lecanemab 700 milligram (mg), as single fixed dose SC injection in the abdomen on Day 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lecanemab</intervention_name>
    <description>Lecanemab IV infusion.</description>
    <arm_group_label>Lecanemab 10 mg/kg</arm_group_label>
    <other_name>BAN2401</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lecanemab</intervention_name>
    <description>Lecanemab SC injection.</description>
    <arm_group_label>Lecanemab 700 mg</arm_group_label>
    <other_name>BAN2401</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Participants must meet all of the following criteria to be included in this study:&#xD;
&#xD;
          1. Non-smoking, male or female, age greater than or equal to (&gt;=) 18 years and less than&#xD;
             or equal to (&lt;=) 65 years old at the time of informed consent. To be considered&#xD;
             non-smokers, participants must have discontinued smoking for at least 4 weeks before&#xD;
             dosing.&#xD;
&#xD;
          2. Japanese participants (age &gt;=20 years) must have been born in Japan of Japanese&#xD;
             parents and Japanese grandparents, must have lived no more than 5 years outside of&#xD;
             Japan, and must not have changed their lifestyle or habits, including diet, while&#xD;
             living outside of Japan.&#xD;
&#xD;
          3. Body Mass Index (BMI) &gt;=18 and less than (&lt;) 30 kilogram per square meter (kg/m^2) at&#xD;
             screening.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Participants who meet any of the following criteria will be excluded from this study:&#xD;
&#xD;
          1. Clinically significant illness that requires medical treatment within 8 weeks or a&#xD;
             clinically significant infection that requires medical treatment within 4 weeks of&#xD;
             dosing.&#xD;
&#xD;
          2. Evidence of disease that may influence the outcome of the study within 4 weeks before&#xD;
             dosing; example, psychiatric disorders and disorders of the gastrointestinal tract,&#xD;
             liver, kidney, respiratory system, endocrine system, hematological system,&#xD;
             neurological system, or cardiovascular system, or subjects who have a congenital&#xD;
             abnormality in metabolism&#xD;
&#xD;
          3. Exposure within the last 14 days before dosing to an individual with confirmed or&#xD;
             probable corona virus disease-2019 (COVID-19) or symptoms within the last 14 days that&#xD;
             are on the most recent Centers for Disease Control and Prevention list of COVID&#xD;
             symptoms or any other reason to consider the participant at potential risk for&#xD;
             COVID-19 infection&#xD;
&#xD;
          4. Participants who had received COVID vaccine but are not 14 days post full vaccination&#xD;
             before dosing&#xD;
&#xD;
          5. Currently enrolled in another clinical study or used any investigational drug or&#xD;
             device within 28 days or 5 half-lives of the other investigational drug, whichever is&#xD;
             longer, preceding informed consent&#xD;
&#xD;
          6. Prior exposure to lecanemab&#xD;
&#xD;
          7. Hypersensitivity to lecanemab or any of the excipients, or to any monoclonal antibody&#xD;
             treatment&#xD;
&#xD;
        NOTE-Other protocol defined Inclusion/Exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Eisai Medical Information</last_name>
    <phone>+1-888-274-2378</phone>
    <email>esi_medinfo@eisai.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Anaheim Clinical Trials</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 7, 2021</study_first_submitted>
  <study_first_submitted_qc>September 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 16, 2021</study_first_posted>
  <last_update_submitted>October 4, 2021</last_update_submitted>
  <last_update_submitted_qc>October 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lecanemab</keyword>
  <keyword>Bioavailability</keyword>
  <keyword>Subcutaneous</keyword>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Eisai's data sharing commitment and further information on how to request data can be found on our website http://eisaiclinicaltrials.com/.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

